Clinical profiles and long-term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 2, 2012, Pages 169-176

  Ben, Qiwen ^a   Xu, Maojin ^a   Jiang, Ying ^b   Yuan, Yaozong ^c   Wang, Kaixuan ^a   Fang, Jun ^a   Li, Zhaoshen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Clinical profiles; Diabetes mellitus; Differentiated diagnosis; Pancreatic ductal adenocarcinoma; Prognosis

Indexed keywords

ADULT; ARTICLE; BODY MASS; CANCER INVASION; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; AGE OF ONSET; AGED; BLOOD GLUCOSE; CARCINOMA, PANCREATIC DUCTAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863034548     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1284     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Du YQLZ, Jin ZD. Endoscope-assisted brachytherapy for pancreatic cancer: from tumor killing to pain relief and drainage. J Interv Gastroenterol 2011; 1: 23-27.
3. Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, et al. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 2007; 67: 1943-1949.
4. Furukawa H, Okada S, Saisho H, Ariyama J, Karasawa E, Nakaizumi A, et al. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996; 78: 986-990.
5. Shimizu Y, Yasui K, Matsueda K, Yanagisawa A, Yamao K. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005; 20: 1591-1594.
6. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42-51.
7. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Jama 1995; 273: 1605-1609.
8. Huxley R, Ansary-Moghaddam A. Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083.
9. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504-511.
10. Ben Q, Cai Q, Li Z, et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 2011; 47: 248-254.
11. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95-101.
12. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 88-95.
13. Gupta S, Vittinghoff E, Bertenthal D, et al. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol 2006; 4: 1366-1372; quiz 1301.
14. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-987.
15. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047-1050.
16. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010; 17: 502-513.
17. Gangi S, Fletcher JG, Nathan MA, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 2004; 182: 897-903.
18. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007; 102: 2157-2163.
19. Ganti AK, Potti A, Koch M, et al. Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma: a series of 308 cases. Med Oncol 2002; 19: 233-237.
20. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, Janiak A, Malecka-Panas E. Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma 2003; 50: 383-387.
21. Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol 2001; 6: 50-54.
22. Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer 2011; 128: 1179-1186.
23. Lh S. TNM, sixth edition: new developments in general concepts and rules. Seminars in surgical oncology 2003; 21: 19-22.
24. Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiiwa K, Mizumoto K, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002; 94: 2344-2349.
25. Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009; 104: 2318-2325.
26. Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 2010; 105: 1661-1669.
27. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159: 101-107.
28. Basso D, Brigato L, Veronesi A, Panozzo MP, Amadori A, Plebani M. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res 1995; 15: 2585-2588.
29. Basso D, Millino C, Greco E, Romualdi C, Fogar P, Valerio A, et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 2004; 53: 1159-1166.
30. Basso D, Valerio A, Seraglia R, Mazza S, Piva MG, Greco E, et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 2002; 24: 8-14.
31. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, et al. Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin Chim Acta 2005; 357: 184-189.
32. Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology 1998; 114: 130-138.
33. Chu CK, Mazo AE, Sarmiento JM, et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. J Am Coll Surg 2010; 210: 463-473.
34. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996; 83: 625-631.
35. Wang F, Larsson J, Adrian TE, Gasslander T, Permert J. In vitro influences between pancreatic adenocarcinoma cells and pancreatic islets. J Surg Res 1998; 79: 13-19.
36. Musey VC, Goldstein S, Farmer PK, Moore PB, Phillips LS. Differential regulation of IGF-1 and IGF-binding protein-1 by dietary composition in humans. Am J Med Sci 1993; 305: 131-138.
37. Zhou L, Zhang R, Wang L, Shen S, Okamoto H, Sugawara A, et al. Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes. Int J Cancer 2010; 127: 1795-1803.
38. Morss AS, Edelman ER. Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem 2007; 282: 14635-14644.